W.B. Saunders for the American Gastroenterological Association
Clinical Gastroenterology and Hepatology vol:13 issue:3 pages:514-521.e4
The addition of immunomodulators increases the efficacy of maintenance therapy with infliximab, for up to 1 year, in patients with Crohn's disease who have not been previously treated with immunomodulators. However, there are questions about the effect of withdrawing immunomodulator therapy from these patients. We studied the effects of treatment with infliximab and immunomodulators (co-treatment) and then immunomodulator withdrawal on long-term outcomes of patients, as well as trough levels of infliximab and formation of anti-infliximab antibodies (ATI).